Banyu Pharmaceutical Confirms Efficacy of Propecia in Long-term Administration.
Tokyo, Japan, May 30, 2006 - (JCN) - On May 29, Banyu
Pharmaceutical announced that the results of its recent trial of
Propecia, an agent for the treatment of androgenetic alopecia (AGA),
have been published in the May 16 issue of Japanese Journal of Clinical
Dermatology, an academic dermatology journal.
According to the journal, the company has confirmed the safety and
efficacy of Propecia Tablet 1mg in a 3-year administration. Propecia
(finasteride), which was developed by Merck & Co., is indicated for
the treatment of male pattern hair loss on the vertex and anterior
mid-scalp area.
Copyright [c] 2006 Japan Corporate News Network. All rights
reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion